REINVENTING HOW HEALTHCARE PROFESSIONALS AND PATIENTS MANAGE PAIN
Virpax Pharmaceuticals is committed to developing patented non-addictive product candidates that manage pain and its complexities, while providing treatment options and minimizing risks to patients and society. By combining compatible drug compounds with our cutting‑edge drug-delivery platforms, we strive to maximize our products’ capabilities and successfully bring them to market. We believe our proprietary drug- delivery platforms will reinvent how patients and prescribers manage pain worldwide.
We are advancing our robust Rx pipeline using our proprietary drug delivery platforms to provide non-addictive treatment alternatives in the management of pain and CNS disorders. Our Molecular Envelope Technology (MET) and liposomal hydrogel technology will significantly improve our drug delivery characteristics by directly targeting pain and CNS Disorder symptoms at their source.
CNS Growth Opportunities
Our patented MET platform is being used to grow our Central Nervous System (CNS) disorder pipeline. The current CNS product indications include Post Traumatic Stress Disorder (PTSD), and Rare Pediatric Epilepsy. We believe the MET may be used to deliver molecules to manage symptoms related to other neurodegenerative and neurotransmission disorders, including Parkinson’s, Alzheimer’s, Cancer Cachexia (multi-organ systemic inflammation), and Migraines.
“Over the past 40 years, the Orphan Drug Act (ODA) has established a strong foundation for the biotech community to invest in and develop new medicines for rare diseases,” says Amanda Malakoff, Executive Director, Rare Disease Company Coalition. “We need to build on that strong foundation so we can ensure continued innovation for the 95% of rare diseases that currently have no approved treatments.”
Rare Disease Company Coalition
JANUARY 3, 2023
Prescribers, regulators, and patients all seek non-addictive treatment options to combat the opioid epidemic.
FDA takes steps aimed at fostering development of non-addictive alternatives to opioids for acute pain management lasting up to 30 days, in response to some form of tissue injury, such as trauma or surgery.
The accelerating development of new treatments and devices are top six on the FDA priority list.
We are continuously strengthening our worldwide patents in the development of non-addictive treatments for pain and degenerative neurological disorders, including rare and orphan diseases.
We are seeking FDA approval for a robust pipeline of product candidates that will radically change how clinicians prescribe pain and CNS disorder therapies in the future.